GLP-1 weight loss drugs are changing how people eat out, pushing diners toward smaller orders and cheaper restaurant meals.

Real-world data on the use of GLP-1 drugs such as Wegovy suggest that some patients can maintain weight loss 6 months after ...

Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose ...

Diabetes care is undergoing a major transformation driven by GLP-1 receptor agonists, which have expanded beyond glycemic ...

With more Black women over 40 using GLP-1s, we break down the risks when it comes to micro-dosing the drug for menopausal weight gain.

U.S. airlines stand to reap the benefits as more passengers slim down thanks to the popularity of GLP-1 weight-loss drugs.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.

AbbVie Inc. (NYSE: ABBV) is one of the 10 Goldman Sachs undervalued stocks to invest in.

Friendly” labels on the packaging are becoming more common in U.S. supermarkets as a growing number of Americans try obesity ...

Research is suggesting that consuming substances like ketamine and MDMA could make it easier to make lifestyle changes, but ...